OptiNose, Inc.
Nasal spray and inhaled pharmaceutical formulations for ENT and allergy diseases
- Sector
- Biotech
- Headquarters
- Yardley, PA
- Founded
- 2010
- Latest Form D
- $4.7M, May 2024
- Total capital
- $115M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $115M
- 8 Form D · last May 2024
- 29 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 22 pending · first 2023
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$4.7M
- Private capital raisedForm D · SEC · 7th filing$4M
- Private capital raisedForm D · SEC · 6th filing$250K
- Private capital raisedForm D · SEC · 5th filing$5.4M
- Private capital raisedForm D · SEC · 4th filing$35M
- Private capital raisedForm D · SEC · 3rd filing$15M
- Private capital raisedForm D · SEC · 2nd filing$30M
- Private capital raisedForm D · SEC · 1st filing$21.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing in Biotech · 4373 companies
Line = median- Federal contractsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Henrik AndersenExecutive OfficerNamed in SEC Form D filings
- Eric BednarskiDirectorNamed in SEC Form D filings
- Victor ClavelliExecutive OfficerNamed in SEC Form D filings
- Klaas de BoerDirectorNamed in SEC Form D filings
- Klaas De BoerDirectorNamed in SEC Form D filings
- Kyle DempseyDirectorNamed in SEC Form D filings
Show all 30 people
- Helena DjupeslandExecutive OfficerNamed in SEC Form D filings
- Per DjupeslandDirector, Executive OfficerNamed in SEC Form D filings
- William DoyleDirectorNamed in SEC Form D filings
- R. FletcherDirectorNamed in SEC Form D filings
- Tom GibbsExecutive OfficerNamed in SEC Form D filings
- Keith GoldanExecutive OfficerNamed in SEC Form D filings
- Wilhelmus GroenhuysenDirectorNamed in SEC Form D filings
- Sandra HeltonDirectorNamed in SEC Form D filings
- Tomas HeymanDirectorNamed in SEC Form D filings
- Michele JanisExecutive OfficerNamed in SEC Form D filings
- Anthony KrickExecutive OfficerNamed in SEC Form D filings
- Ramy MahmoudDirector, Executive OfficerNamed in SEC Form D filings
- Michael MarinoExecutive OfficerNamed in SEC Form D filings
- Peter MillerDirector, Executive OfficerNamed in SEC Form D filings
- Robert O'NeilDirectorNamed in SEC Form D filings
- Patrick O'NeillDirectorNamed in SEC Form D filings
- Catherine OwenDirectorNamed in SEC Form D filings
- Jackson PhillipsDirectorNamed in SEC Form D filings
- Larry PickeringDirectorNamed in SEC Form D filings
- Joseph ScodariDirectorNamed in SEC Form D filings
- Paul SpenceExecutive OfficerNamed in SEC Form D filings
- Joshua TamaroffDirectorNamed in SEC Form D filings
- Terrence TerifayExecutive OfficerNamed in SEC Form D filings
- Sriram VenkataramanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 27- PendingNasal AdministrationUSPTOApplication 19640922
- GrantedNasal AdministrationUSPTOUS 12,616,806
- PendingNasal Delivery DevicesUSPTOApplication 19394580
Show all 27 patent records
- Nasal AdministrationAug 20, 2026 · Application 19640922Pending
- Nasal AdministrationMay 5, 2026 · US 12,616,806Granted
- Nasal Delivery DevicesMar 12, 2026 · Application 19394580Pending
- Nasal Delivery DevicesDec 23, 2025 · US 12,502,497Granted
- Nasal AdministrationNov 6, 2025 · Application 19268638Pending
- Nasal DeliveryAug 21, 2025 · Application 19027027Pending
- Nasal Delivery DevicesJul 24, 2025 · Application 19027278Pending
- Intranasal AdministrationApr 10, 2025 · Application 18889476Pending
- Nasal AdministrationMar 20, 2025 · Application 18643434Pending
- Delivery Device And MethodMar 13, 2025 · Application 18800200Pending
- Nasal Delivery DevicesMar 13, 2025 · Application 18753474Pending
- Nasal DeliveryNov 30, 2023 · Application 18310647Pending
- Intranasal AdministrationNov 23, 2023 · Application 18205580Pending
- Methods For Treating Chronic RhinosinusitisSep 14, 2023 · Application 18179178Pending
- Intranasal AdministrationAug 22, 2023 · US 11,730,904Granted
- Nasal Delivery DevicesAug 10, 2023 · Application 18109326Pending
- Intranasal AdministrationJul 25, 2023 · US 11,707,586Granted
- Powder Delivery DevicesJun 15, 2023 · Application 18164836Pending
- Nasal Delivery DevicesMar 14, 2023 · US 11,602,603Granted
- Nasal DeliveryNov 3, 2022 · Application 17675336Pending
- Exhalation Delivery System For And Method Of Treating Sinus DiseaseSep 22, 2022 · Application 17281290Pending
- Nasal Delivery DevicesMay 19, 2022 · Application 17305269Pending
- Nasal DeliveryMar 31, 2022 · Application 17341780Pending
- Intranasal AdministrationNov 11, 2021 · Application 17329225Pending
- Nasal Delivery DevicesSep 23, 2021 · Application 17316779Pending
- Nasal DeliveryJul 22, 2021 · Application 17153962Pending
- Nasal Delivery DevicesJan 23, 2020 · Application 16525716Pending
Related companies, and why
- Pacylex Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Angstrom Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Aliada TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Telo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Phenomune, LLCSimilar federal contract value in Biotech · null in contracts
- Manifold Technologies Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .